The resolution rate of Enhertu's treatment of patients with brain metastases of HER2-positive breast cancer reached 73.3%! 29/11/2023
Trodvy® received a positive opinion from CHMP for the treatment of HR+/HER2-metastatic breast cancer 12/07/2023
